NeoGenomics Q3 Sales Beat Estimates, Stock Surges

Tuesday, Oct 28, 2025 7:59 am ET1min read

NeoGenomics (NASDAQ:NEO) reported Q3 sales of $187.8 million, up 11.9% YoY, beating analysts' estimates. The company's non-GAAP profit of $0.03 per share was in line with estimates. NeoGenomics reconfirmed its full-year revenue guidance of $723 million and reiterated its adjusted EPS guidance of $0.10.

NeoGenomics Q3 Sales Beat Estimates, Stock Surges

Comments



Add a public comment...
No comments

No comments yet